How Many ChemoCentryx, Inc. (NASDAQ:CCXI)’s Analysts Are Bearish?

January 28, 2018 - By Stephen Andrade

 How Many ChemoCentryx, Inc. (NASDAQ:CCXI)'s Analysts Are Bearish?
Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.26, from 1.4 in 2017Q2. It fall, as 12 investors sold ChemoCentryx, Inc. shares while 23 reduced holdings. 12 funds opened positions while 28 raised stakes. 23.75 million shares or 2.21% less from 24.29 million shares in 2017Q2 were reported.
Banque Pictet Cie Sa owns 54,178 shares. 62,800 are owned by California Pub Employees Retirement System. Keybank Natl Association Oh, a Ohio-based fund reported 40,438 shares. Acadian Asset Mngmt Ltd Limited Liability Company has invested 0.02% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Rhumbline Advisers has 29,953 shares. Tower Rech Cap Limited Company (Trc) stated it has 4,461 shares or 0% of all its holdings. California State Teachers Retirement Sys holds 0% or 38,082 shares in its portfolio. New York-based Blackrock has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Jacobs Levy Equity Management has invested 0.02% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Artal Sa stated it has 500,000 shares. 53,046 were reported by Bridgeway. D E Shaw Communications has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). First Quadrant Ltd Partnership Ca holds 0% or 23,349 shares. Northern Trust holds 0% or 275,945 shares in its portfolio. Los Angeles Cap Equity Research Incorporated accumulated 55,780 shares.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Among 3 analysts covering ChemoCentryx (NASDAQ:CCXI), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. ChemoCentryx had 5 analyst reports since September 3, 2015 according to SRatingsIntel. The firm has “Sell” rating by Zacks given on Thursday, September 3. The firm earned “Buy” rating on Thursday, August 10 by JMP Securities. The rating was maintained by Cowen & Co on Tuesday, August 8 with “Hold”. On Tuesday, February 21 the stock rating was initiated by JMP Securities with “Mkt Outperform”. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Sell” rating by Zacks on Monday, September 21. Below is a list of ChemoCentryx, Inc. (NASDAQ:CCXI) latest ratings and price target changes.

10/08/2017 Broker: JMP Securities Rating: Buy New Target: $13.0000 Maintain
08/08/2017 Broker: Cowen & Co Rating: Hold Maintain

The stock increased 3.00% or $0.28 during the last trading session, reaching $9.62. About 261,960 shares traded or 78.06% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 60.64% since January 28, 2017 and is uptrending. It has outperformed by 43.94% the S&P500.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $469.14 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

More recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: which released: “ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor …” on January 22, 2018. Also published the news titled: “ChemoCentryx to Present at the 36th Annual JP Morgan Healthcare Conference” on January 03, 2018.‘s news article titled: “ChemoCentryx Secures up to $100 Million in New Capital Commitments” with publication date: January 04, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.